GlassScriptPhysician profile
Pamela N Murray
NPI 1851608590
$17,154.96
in general payments reported to CMS, 2019-2025
33 companies · $2,874 in 2025
The $2,874 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,225 · 2022: $3,460 · 2023: $4,033 · 2024: $3,563 · 2025: $2,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,629 · Consulting Fee: $552 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,628.94 |
| Consulting Fee | $552.00 |
| Education | $288.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,450.30 | 2021-2025 | |
| Janssen Biotech, INC. | $2,046.16 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $2,043.05 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,382.35 | 2021-2025 | Siliq, Arazlo, Jublia |
| Lilly USA, LLC | $982.76 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $913.31 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $791.09 | 2021-2025 | Sotyktu |
| Dermavant Sciences, INC. | $781.07 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $765.50 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $708.77 | 2021-2025 | Aklief, Oracea, Epsolay |
| Arcutis Biotherapeutics, INC. | $670.26 | 2023-2025 | Zoryve |
| Incyte Corporation | $624.24 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $604.10 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $574.76 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $391.94 | 2021-2025 | Bimzelx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $369.96 | 2022-2025 | |
| Genzyme Corporation | $274.32 | 2021-2025 | |
| Almirall LLC | $187.74 | 2021-2025 | Klisyri, Seysara |
| Organon LLC | $156.31 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $60.25 | 2021 | |
| Biofrontera INC. | $50.80 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Nabriva Therapeutics, Plc | $41.32 | 2021-2022 | |
| Fidia Pharma USA INC. | $37.75 | 2024-2025 | |
| Medimetriks Pharmaceuticals, INC. | $37.40 | 2023-2025 | Clindacin Etz, Neo-Synalar |
| Genentech USA, INC. | $34.84 | 2021-2022 | |
| Journey Medical Corporation | $31.67 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $30.03 | 2021-2022 | |
| Merz North America, INC. | $26.48 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.97 | 2023 | Spevigo |
| Botanix Sb INC | $18.74 | 2025 | Sofdra |
| Epi Health, LLC | $16.34 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.15 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.